Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,220
archived clinical trials in
HIV / AIDS

Medications for Chronic HIV: Education and Collaboration
Implementing Computerized Clinical Assessment of HIV Patient Adherence
Status: Enrolling
Updated:  2/17/2018
Boston Med Ctr
mi
from
Boston, MA
Medications for Chronic HIV: Education and Collaboration
Implementing Computerized Clinical Assessment of HIV Patient Adherence
Status: Enrolling
Updated: 2/17/2018
Boston Med Ctr
mi
from
Boston, MA
Click here to add this to my saved trials
Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma
Single-Arm, Dose-Finding Pilot Trial of Single-Agent Bortezomib in Patients With Relapsed/Refractory AIDS-Associated Kaposi Sarcoma With Correlative Assessments of KSHV and HIV
Status: Enrolling
Updated:  2/19/2018
UC San Diego Moores Cancer Center
mi
from
La Jolla, CA
Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma
Single-Arm, Dose-Finding Pilot Trial of Single-Agent Bortezomib in Patients With Relapsed/Refractory AIDS-Associated Kaposi Sarcoma With Correlative Assessments of KSHV and HIV
Status: Enrolling
Updated: 2/19/2018
UC San Diego Moores Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma
Single-Arm, Dose-Finding Pilot Trial of Single-Agent Bortezomib in Patients With Relapsed/Refractory AIDS-Associated Kaposi Sarcoma With Correlative Assessments of KSHV and HIV
Status: Enrolling
Updated:  2/19/2018
UCLA, Center for Clinical AIDS Research and Education
mi
from
Los Angeles, CA
Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma
Single-Arm, Dose-Finding Pilot Trial of Single-Agent Bortezomib in Patients With Relapsed/Refractory AIDS-Associated Kaposi Sarcoma With Correlative Assessments of KSHV and HIV
Status: Enrolling
Updated: 2/19/2018
UCLA, Center for Clinical AIDS Research and Education
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma
Single-Arm, Dose-Finding Pilot Trial of Single-Agent Bortezomib in Patients With Relapsed/Refractory AIDS-Associated Kaposi Sarcoma With Correlative Assessments of KSHV and HIV
Status: Enrolling
Updated:  2/19/2018
UCLA Jonsson Comprehensive Cancer Center
mi
from
Los Angeles, CA
Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma
Single-Arm, Dose-Finding Pilot Trial of Single-Agent Bortezomib in Patients With Relapsed/Refractory AIDS-Associated Kaposi Sarcoma With Correlative Assessments of KSHV and HIV
Status: Enrolling
Updated: 2/19/2018
UCLA Jonsson Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma
Single-Arm, Dose-Finding Pilot Trial of Single-Agent Bortezomib in Patients With Relapsed/Refractory AIDS-Associated Kaposi Sarcoma With Correlative Assessments of KSHV and HIV
Status: Enrolling
Updated:  2/19/2018
University of California, San Diego
mi
from
San Diego, CA
Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma
Single-Arm, Dose-Finding Pilot Trial of Single-Agent Bortezomib in Patients With Relapsed/Refractory AIDS-Associated Kaposi Sarcoma With Correlative Assessments of KSHV and HIV
Status: Enrolling
Updated: 2/19/2018
University of California, San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma
Single-Arm, Dose-Finding Pilot Trial of Single-Agent Bortezomib in Patients With Relapsed/Refractory AIDS-Associated Kaposi Sarcoma With Correlative Assessments of KSHV and HIV
Status: Enrolling
Updated:  2/19/2018
Johns Hopkins University-Sidney Kimmel Cancer Center
mi
from
Baltimore, MD
Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma
Single-Arm, Dose-Finding Pilot Trial of Single-Agent Bortezomib in Patients With Relapsed/Refractory AIDS-Associated Kaposi Sarcoma With Correlative Assessments of KSHV and HIV
Status: Enrolling
Updated: 2/19/2018
Johns Hopkins University-Sidney Kimmel Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma
Single-Arm, Dose-Finding Pilot Trial of Single-Agent Bortezomib in Patients With Relapsed/Refractory AIDS-Associated Kaposi Sarcoma With Correlative Assessments of KSHV and HIV
Status: Enrolling
Updated:  2/19/2018
Boston Med Ctr
mi
from
Boston, MA
Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma
Single-Arm, Dose-Finding Pilot Trial of Single-Agent Bortezomib in Patients With Relapsed/Refractory AIDS-Associated Kaposi Sarcoma With Correlative Assessments of KSHV and HIV
Status: Enrolling
Updated: 2/19/2018
Boston Med Ctr
mi
from
Boston, MA
Click here to add this to my saved trials
Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma
Single-Arm, Dose-Finding Pilot Trial of Single-Agent Bortezomib in Patients With Relapsed/Refractory AIDS-Associated Kaposi Sarcoma With Correlative Assessments of KSHV and HIV
Status: Enrolling
Updated:  2/19/2018
Memorial Sloan Kettering-Rockefeller Outpatient Pavilion
mi
from
New York, NY
Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma
Single-Arm, Dose-Finding Pilot Trial of Single-Agent Bortezomib in Patients With Relapsed/Refractory AIDS-Associated Kaposi Sarcoma With Correlative Assessments of KSHV and HIV
Status: Enrolling
Updated: 2/19/2018
Memorial Sloan Kettering-Rockefeller Outpatient Pavilion
mi
from
New York, NY
Click here to add this to my saved trials
Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma
Single-Arm, Dose-Finding Pilot Trial of Single-Agent Bortezomib in Patients With Relapsed/Refractory AIDS-Associated Kaposi Sarcoma With Correlative Assessments of KSHV and HIV
Status: Enrolling
Updated:  2/19/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma
Single-Arm, Dose-Finding Pilot Trial of Single-Agent Bortezomib in Patients With Relapsed/Refractory AIDS-Associated Kaposi Sarcoma With Correlative Assessments of KSHV and HIV
Status: Enrolling
Updated: 2/19/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma
Single-Arm, Dose-Finding Pilot Trial of Single-Agent Bortezomib in Patients With Relapsed/Refractory AIDS-Associated Kaposi Sarcoma With Correlative Assessments of KSHV and HIV
Status: Enrolling
Updated:  2/19/2018
Virginia Mason Medical Center
mi
from
Seattle, WA
Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma
Single-Arm, Dose-Finding Pilot Trial of Single-Agent Bortezomib in Patients With Relapsed/Refractory AIDS-Associated Kaposi Sarcoma With Correlative Assessments of KSHV and HIV
Status: Enrolling
Updated: 2/19/2018
Virginia Mason Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Advancing HIV Prevention and Linkage to Care Among MSM With Gamification
Advancing HIV Prevention and Linkage to Care Among MSM With Gamification
Status: Enrolling
Updated:  2/20/2018
AHF Hollywood Wellness Center
mi
from
Los Angeles, CA
Advancing HIV Prevention and Linkage to Care Among MSM With Gamification
Advancing HIV Prevention and Linkage to Care Among MSM With Gamification
Status: Enrolling
Updated: 2/20/2018
AHF Hollywood Wellness Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Advancing HIV Prevention and Linkage to Care Among MSM With Gamification
Advancing HIV Prevention and Linkage to Care Among MSM With Gamification
Status: Enrolling
Updated:  2/20/2018
AHF Wellness Center Oakland
mi
from
Oakland, CA
Advancing HIV Prevention and Linkage to Care Among MSM With Gamification
Advancing HIV Prevention and Linkage to Care Among MSM With Gamification
Status: Enrolling
Updated: 2/20/2018
AHF Wellness Center Oakland
mi
from
Oakland, CA
Click here to add this to my saved trials
Durability of Adherence in Self-Management of HIV
Durability of Adherence in Self-Management of HIV
Status: Enrolling
Updated:  2/21/2018
Ucsd, Avrc Crs
mi
from
San Diego, CA
Durability of Adherence in Self-Management of HIV
Durability of Adherence in Self-Management of HIV
Status: Enrolling
Updated: 2/21/2018
Ucsd, Avrc Crs
mi
from
San Diego, CA
Click here to add this to my saved trials
Durability of Adherence in Self-Management of HIV
Durability of Adherence in Self-Management of HIV
Status: Enrolling
Updated:  2/21/2018
Barranco CRS (11301)
mi
from
Lima,
Durability of Adherence in Self-Management of HIV
Durability of Adherence in Self-Management of HIV
Status: Enrolling
Updated: 2/21/2018
Barranco CRS (11301)
mi
from
Lima,
Click here to add this to my saved trials
Pilot Study of Effect of Kaletra on CD4 Response in HIV Positive (+) Patients With Viral Suppression KIMBO Study
The Effect of Kaletra on CD4 Immune Reconstitution in HIV-infected Patients With Long-term Virologic Suppression on a Non-Kaletra Containing ART Regimen, But With a Blunted Immune Response
Status: Enrolling
Updated:  2/23/2018
Univ of Maryland, Institute of Human Virology
mi
from
Baltimore, MD
Pilot Study of Effect of Kaletra on CD4 Response in HIV Positive (+) Patients With Viral Suppression KIMBO Study
The Effect of Kaletra on CD4 Immune Reconstitution in HIV-infected Patients With Long-term Virologic Suppression on a Non-Kaletra Containing ART Regimen, But With a Blunted Immune Response
Status: Enrolling
Updated: 2/23/2018
Univ of Maryland, Institute of Human Virology
mi
from
Baltimore, MD
Click here to add this to my saved trials
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated:  2/26/2018
Children's Hospital of Los Angeles NICHD CRS
mi
from
Los Angeles, CA
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated: 2/26/2018
Children's Hospital of Los Angeles NICHD CRS
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated:  2/26/2018
Univ. of California San Francisco NICHD CRS
mi
from
San Francisco, CA
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated: 2/26/2018
Univ. of California San Francisco NICHD CRS
mi
from
San Francisco, CA
Click here to add this to my saved trials
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated:  2/26/2018
Howard Univ. Washington DC NICHD CRS
mi
from
Washington,
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated: 2/26/2018
Howard Univ. Washington DC NICHD CRS
mi
from
Washington,
Click here to add this to my saved trials
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated:  2/26/2018
Children's National Med. Ctr. Washington DC NICHD CRS
mi
from
Washington,
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated: 2/26/2018
Children's National Med. Ctr. Washington DC NICHD CRS
mi
from
Washington,
Click here to add this to my saved trials
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated:  2/26/2018
Univ. of Florida Jacksonville NICHD CRS
mi
from
Jacksonville, FL
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated: 2/26/2018
Univ. of Florida Jacksonville NICHD CRS
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated:  2/26/2018
USF - Tampa NICHD CRS
mi
from
Tampa, FL
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated: 2/26/2018
USF - Tampa NICHD CRS
mi
from
Tampa, FL
Click here to add this to my saved trials
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated:  2/26/2018
Rush Univ. Cook County Hosp. Chicago NICHD CRS
mi
from
Chicago, IL
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated: 2/26/2018
Rush Univ. Cook County Hosp. Chicago NICHD CRS
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated:  2/26/2018
Tulane Univ. New Orleans NICHD CRS
mi
from
New Orleans, LA
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated: 2/26/2018
Tulane Univ. New Orleans NICHD CRS
mi
from
New Orleans, LA
Click here to add this to my saved trials
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated:  2/26/2018
Johns Hopkins Univ. Baltimore NICHD CRS
mi
from
Baltimore, MD
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated: 2/26/2018
Johns Hopkins Univ. Baltimore NICHD CRS
mi
from
Baltimore, MD
Click here to add this to my saved trials
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated:  2/26/2018
Children's Hosp. of Boston NICHD CRS
mi
from
Boston, MA
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated: 2/26/2018
Children's Hosp. of Boston NICHD CRS
mi
from
Boston, MA
Click here to add this to my saved trials
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated:  2/26/2018
Boston Medical Center Ped. HIV Program NICHD CRS
mi
from
Boston, MA
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated: 2/26/2018
Boston Medical Center Ped. HIV Program NICHD CRS
mi
from
Boston, MA
Click here to add this to my saved trials
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated:  2/26/2018
Jacobi Med. Ctr. Bronx NICHD CRS
mi
from
Bronx, NY
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated: 2/26/2018
Jacobi Med. Ctr. Bronx NICHD CRS
mi
from
Bronx, NY
Click here to add this to my saved trials
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated:  2/26/2018
Nyu Ny Nichd Crs
mi
from
New York, NY
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated: 2/26/2018
Nyu Ny Nichd Crs
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated:  2/26/2018
Metropolitan Hosp. NICHD CRS
mi
from
New York, NY
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated: 2/26/2018
Metropolitan Hosp. NICHD CRS
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated:  2/26/2018
Columbia IMPAACT CRS
mi
from
New York, NY
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated: 2/26/2018
Columbia IMPAACT CRS
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated:  2/26/2018
SUNY Stony Brook NICHD CRS
mi
from
Stony Brook, NY
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated: 2/26/2018
SUNY Stony Brook NICHD CRS
mi
from
Stony Brook, NY
Click here to add this to my saved trials
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated:  2/26/2018
DUMC Ped. CRS
mi
from
Durham, NC
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated: 2/26/2018
DUMC Ped. CRS
mi
from
Durham, NC
Click here to add this to my saved trials
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated:  2/26/2018
Texas Children's Hosp. CRS
mi
from
Houston, TX
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated: 2/26/2018
Texas Children's Hosp. CRS
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated:  2/26/2018
Usc La Nichd Crs
mi
from
Alhambra, CA
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated: 2/26/2018
Usc La Nichd Crs
mi
from
Alhambra, CA
Click here to add this to my saved trials
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated:  2/26/2018
University of California, UC San Diego CRS
mi
from
La Jolla, CA
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated: 2/26/2018
University of California, UC San Diego CRS
mi
from
La Jolla, CA
Click here to add this to my saved trials
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated:  2/26/2018
David Geffen School of Medicine at UCLA NICHD CRS
mi
from
Los Angeles, CA
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated: 2/26/2018
David Geffen School of Medicine at UCLA NICHD CRS
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated:  2/26/2018
Univ. of Colorado Denver NICHD CRS
mi
from
Aurora, CO
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated: 2/26/2018
Univ. of Colorado Denver NICHD CRS
mi
from
Aurora, CO
Click here to add this to my saved trials
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated:  2/26/2018
South Florida CDTC Ft Lauderdale NICHD CRS
mi
from
Fort Lauderdale, FL
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated: 2/26/2018
South Florida CDTC Ft Lauderdale NICHD CRS
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated:  2/26/2018
Ann & Robert H. Lurie Children's Hospital of Chicago (LCH) CRS
mi
from
Chicago, IL
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated: 2/26/2018
Ann & Robert H. Lurie Children's Hospital of Chicago (LCH) CRS
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated:  2/26/2018
WNE Maternal Pediatric Adolescent AIDS CRS
mi
from
Worcester, MA
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated: 2/26/2018
WNE Maternal Pediatric Adolescent AIDS CRS
mi
from
Worcester, MA
Click here to add this to my saved trials
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated:  2/26/2018
Bronx-Lebanon Hospital Center NICHD CRS
mi
from
Bronx, NY
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated: 2/26/2018
Bronx-Lebanon Hospital Center NICHD CRS
mi
from
Bronx, NY
Click here to add this to my saved trials
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated:  2/26/2018
Philadelphia IMPAACT Unit CRS
mi
from
Philadelphia, PA
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated: 2/26/2018
Philadelphia IMPAACT Unit CRS
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated:  2/26/2018
St. Jude Children's Research Hospital CRS
mi
from
Memphis, TN
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated: 2/26/2018
St. Jude Children's Research Hospital CRS
mi
from
Memphis, TN
Click here to add this to my saved trials
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated:  2/26/2018
Seattle Children's Research Institute CRS
mi
from
Seattle, WA
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated: 2/26/2018
Seattle Children's Research Institute CRS
mi
from
Seattle, WA
Click here to add this to my saved trials
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated:  2/26/2018
Hosp. General de Agudos Buenos Aires Argentina NICHD CRS
mi
from
Ciudad de Buenos Aires,
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents
Status: Enrolling
Updated: 2/26/2018
Hosp. General de Agudos Buenos Aires Argentina NICHD CRS
mi
from
Ciudad de Buenos Aires,
Click here to add this to my saved trials
A Study of Saquinavir/Ritonavir in Liver-Impaired Patients With HIV Infection.
Effect of Moderate Liver Impairment on the Pharmacokinetics of Saquinavir After Administration of Saquinavir/Ritonavir 1000/100mg BID in HIV Patients
Status: Enrolling
Updated:  2/28/2018
Clinical Research Facility
mi
from
Chicago, IL
A Study of Saquinavir/Ritonavir in Liver-Impaired Patients With HIV Infection.
Effect of Moderate Liver Impairment on the Pharmacokinetics of Saquinavir After Administration of Saquinavir/Ritonavir 1000/100mg BID in HIV Patients
Status: Enrolling
Updated: 2/28/2018
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of Saquinavir/Ritonavir in Liver-Impaired Patients With HIV Infection.
Effect of Moderate Liver Impairment on the Pharmacokinetics of Saquinavir After Administration of Saquinavir/Ritonavir 1000/100mg BID in HIV Patients
Status: Enrolling
Updated:  2/28/2018
Clinical Research Facility
mi
from
Somers Point, NJ
A Study of Saquinavir/Ritonavir in Liver-Impaired Patients With HIV Infection.
Effect of Moderate Liver Impairment on the Pharmacokinetics of Saquinavir After Administration of Saquinavir/Ritonavir 1000/100mg BID in HIV Patients
Status: Enrolling
Updated: 2/28/2018
Clinical Research Facility
mi
from
Somers Point, NJ
Click here to add this to my saved trials
A Study of Saquinavir/Ritonavir in Liver-Impaired Patients With HIV Infection.
Effect of Moderate Liver Impairment on the Pharmacokinetics of Saquinavir After Administration of Saquinavir/Ritonavir 1000/100mg BID in HIV Patients
Status: Enrolling
Updated:  2/28/2018
Clinical Research Facility
mi
from
Voorhees, NJ
A Study of Saquinavir/Ritonavir in Liver-Impaired Patients With HIV Infection.
Effect of Moderate Liver Impairment on the Pharmacokinetics of Saquinavir After Administration of Saquinavir/Ritonavir 1000/100mg BID in HIV Patients
Status: Enrolling
Updated: 2/28/2018
Clinical Research Facility
mi
from
Voorhees, NJ
Click here to add this to my saved trials
A Study of Saquinavir/Ritonavir in Liver-Impaired Patients With HIV Infection.
Effect of Moderate Liver Impairment on the Pharmacokinetics of Saquinavir After Administration of Saquinavir/Ritonavir 1000/100mg BID in HIV Patients
Status: Enrolling
Updated:  2/28/2018
Clinical Research Facility
mi
from
Philadelphia, PA
A Study of Saquinavir/Ritonavir in Liver-Impaired Patients With HIV Infection.
Effect of Moderate Liver Impairment on the Pharmacokinetics of Saquinavir After Administration of Saquinavir/Ritonavir 1000/100mg BID in HIV Patients
Status: Enrolling
Updated: 2/28/2018
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of Saquinavir/Ritonavir in Liver-Impaired Patients With HIV Infection.
Effect of Moderate Liver Impairment on the Pharmacokinetics of Saquinavir After Administration of Saquinavir/Ritonavir 1000/100mg BID in HIV Patients
Status: Enrolling
Updated:  2/28/2018
Clinical Research Facility
mi
from
Dallas, TX
A Study of Saquinavir/Ritonavir in Liver-Impaired Patients With HIV Infection.
Effect of Moderate Liver Impairment on the Pharmacokinetics of Saquinavir After Administration of Saquinavir/Ritonavir 1000/100mg BID in HIV Patients
Status: Enrolling
Updated: 2/28/2018
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials